



1/14/2021 | COVID-19: US Healthcare
Therapeutics at High Risk for Supply Shortage

Therapeutic Category	Therapeutic Group or Drug	Known Shortages* (as of 1/14/2021)	# of Labelers per Group**	# of Drugs with Single Labeler per Group***
Analgesics	Acetaminophen (oral)		74	-
	Oral opioids for analgesia	Y	133	1
	Parenteral analgesics for acute pain management	Y	39	4
Agents that may be used for severely ill patients	Solutions for dialysis	Y	2	2
	Diluents	Y	143	0
	Fluids for electrolytes and hydration	Y	23	5
	Fluids for irrigation	Y	17	2
	Continuous infusion sedatives	Y	44	5
	Agents for neuromuscular blockade	Y	71	1
	Oxygen		-	-
	Inhaled nitric oxide for acute respiratory distress syndrome (ARDS)		1	1
	Agents for pulmonary hypertension		41	6
	Vasoactive agents for septic shock	Y	31	2
	Injectable corticosteroids	Y	106	-
	Inhalation therapy for asthma	Y	36	1
Antithrombotics for venous thromboembolism (VTE) prophylaxis and treatment	Y	357	2	



COVID-19: Therapeutics at High Risk for Supply Shortage

Therapeutic Category	Therapeutic Group or Drug	Known Shortages* (as of 1/14/2021)	# of Labelers per Group**	# of Drugs with Single Labeler per Group***
Anti-infectives	Broad spectrum antibiotics for bacterial pneumonia	Y	101	2
	Injectable antipseudomonal agents	Y	38	1
	Antibiotics for methicillin-resistant Staphylococcus aureus (MRSA)	Y	123	5
	Injectable macrolide antibiotics	Y	27	1
	Therapies for clostridium difficile (c. diff)-associated diarrhea (CDAD)	Y	69	2
	Antibiotic beta-lactamase inhibitor combinations	Y	48	3
Novel agents under investigation	Novel antivirals		-	-
	Novel vaccines		-	-
Agents being investigated for off-label use against COVID-19	Antiviral agents for treatment of COVID-19 -- Includes remdesivir, hydroxychloroquine, chloroquine, and branded/generic lopinavir-ritonavir	Y	124	1
	Immunomodulatory agents for the treatment of COVID-19 -- Includes the azithromycin products, the interleukin-6 inhibitors, and several additional drugs currently under investigation	Y	47	8

* Groups or drugs experiencing known shortages according to the Food and Drug Administration (FDA) or American Society of Health-System Pharmacists (ASHP) drug shortage lists.

**Labeler information is derived from First Databank drug database, where labeler names may vary slightly from the FDA database -- Please work directly with your primary pharmaceutical distributor (e.g. AmerisourceBergen, Cardinal Health, McKesson) for timely supply of required products.

*** Drugs with a single labeler may pose challenges for healthcare providers when on shortage because there are no alternative manufacturers for these drugs. Thus, alternative formulations for these drugs are likely not available, and providers will need to utilize a therapeutic alternative.

Designates newly-added therapeutic